The multiplex model of the genetics of Alzheimer's disease

R Sims, M Hill, J Williams - Nature neuroscience, 2020 - nature.com
Genes play a strong role in Alzheimer's disease (AD), with late-onset AD showing heritability
of 58–79% and early-onset AD showing over 90%. Genetic association provides a robust …

Alzheimer's disease: a matter of blood–brain barrier dysfunction?

A Montagne, Z Zhao, BV Zlokovic - Journal of Experimental Medicine, 2017 - rupress.org
The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and
pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in …

A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders

D Agarwal, C Sandor, V Volpato, TM Caffrey… - Nature …, 2020 - nature.com
We describe a human single-nuclei transcriptomic atlas for the substantia nigra (SN),
generated by sequencing approximately 17,000 nuclei from matched cortical and SN …

ApoE4: an emerging therapeutic target for Alzheimer's disease

M Safieh, AD Korczyn, DM Michaelson - BMC medicine, 2019 - Springer
Background The growing body of evidence indicating the heterogeneity of Alzheimer's
disease (AD), coupled with disappointing clinical studies directed at a fit-for-all therapy …

Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease

AD Marais - Pathology, 2019 - Elsevier
Summary Apolipoprotein E (apoE), a 34 kDa circulating glycoprotein of 299 amino acids,
predominantly synthesised in the liver, associates with triglyceride-rich lipoproteins to …

Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer's disease

P Baloni, CC Funk, J Yan, JT Yurkovich… - Cell Reports …, 2020 - cell.com
Increasing evidence suggests Alzheimer's disease (AD) pathophysiology is influenced by
primary and secondary bile acids, the end product of cholesterol metabolism. We analyze …

Metabolic dysregulation contributes to the progression of Alzheimer's disease

X Yan, Y Hu, B Wang, S Wang, X Zhang - Frontiers in neuroscience, 2020 - frontiersin.org
Alzheimer's disease (AD) is an incurable neurodegenerative disease. Numerous studies
have demonstrated a critical role for dysregulated glucose metabolism in its pathogenesis …

APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function

M Xiong, H Jiang, JR Serrano, ER Gonzales… - Science translational …, 2021 - science.org
The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-
onset Alzheimer's disease (AD) and greatly influences the development of amyloid-β (Aβ) …

Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism

Q Ma, Z Zhao, AP Sagare, Y Wu, M Wang… - Molecular …, 2018 - Springer
Background Clearance at the blood-brain barrier (BBB) plays an important role in removal of
Alzheimer's amyloid-β (Aβ) toxin from brain both in humans and animal models …

Astrocytes as a therapeutic target in alzheimer's disease–comprehensive review and recent developments

M Rodríguez-Giraldo, RE González-Reyes… - International Journal of …, 2022 - mdpi.com
Alzheimer's disease (AD) is a frequent and disabling neurodegenerative disorder, in which
astrocytes participate in several pathophysiological processes including neuroinflammation …